Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

P24 antigens and antibody: estimation of antigens and antibodies to diagnose HIV

zeihl - Nelsen stain: staining sputum from patients with HIV to detect tubercle bacilli

culture on Lowenstein jensen media: spenciem will be inoculated on LJ media and kept for 2-8 weeks, to see small white colonies

Molecular detection of antibiotic resistance: to see the pattern of antibiotic resistance of tubercle bacilli

Study summary

Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease, including 0.3 million people with human immunodeficiency virus (HIV) infection . TB remains the primary killer of HIV-positive individuals. TB incidence is falling at about 2% per year . Airborne transmission of M. tuberculosis typically causes TB infection in both immunocompetent and immunocompromised hosts and the disease is symptomatic and contagious .

Eligibility

Primary outcome measure(s)

• The Prevalance of tubercuolsis in immunocompetent patients suffereing from chronic chest problems — December 2024- June 2025
  Patients suffering from chronic chest problems will be screened for presence of TB bacilli using chest X-ray, sputum smear, culture on LJ media, detection of DNA of TB bacilli using PCR
• The prevalence of tuberculosis in HIV patients — December 2024- June 2025
  Detection of tubercle bacilli in HIV positive patients , these patients will be screened for presence of TB bacilli using chest X-ray, sputum smear, culture on LJ media, detection of DNA of TB bacilli using PCR

Trial sites (1)

More Sohag University trials in Egypt